Reduced Anticoagulation Targets in ECLS (RATE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.
Also called NCT04536272
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose other
- Phase
- Phase 3
- Enrolled
- 330 participants
- Sponsor
- Registry
-
NCT04536272 -
2019-004125-24
-
- Other papers using this trial's data
- Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT04536272. Randomized; no masking; primary purpose other. Start 2020-10-01 (actual); primary completion 2025-03-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Reduced Anticoagulation Targets in ECLS (RATE)
- Acronym
- RATE
- Condition
- Heart Failure
- Condition
- Respiratory Failure
- Condition
- Extracorporeal Membrane Oxygenation
- Condition
- Bleeding
- Condition
- Thrombosis
- Intervention (Drug)
- Heparin
- Intervention (Drug)
- LMWH
- Lead sponsor
- University Medical Center Groningen
- Collaborator
- ZonMw: The Netherlands Organisation for Health Research and Development
- Collaborator
- Erasmus Medical Center
- Collaborator
- Leiden University Medical Center
- Collaborator
- St. Antonius Hospital
- Collaborator
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Collaborator
- Isala
- Collaborator
- OLVG
- Collaborator
- Radboud University Medical Center
Record details
- Record id
cardio:ct-nct04536272- Content hash
876f3874deb0186c7d3fe17183955e039146e56f84599c88f5bbb585ad7abb01